Major outcomes of haploidentical hematopoietic cell transplantation recipients with different mycophenolate mofetil (MMF) durations
| Longer MMF | Shorter MMF | P value | |
| Subjects, n | 85 | 85 | – |
| EBV reactivation within 100 days, n (%) | 22 (26) | 11 (13) | 0.033 |
| Time to the first EBV reactivation, days | 44 (22–82) | 47 (27–86) | 0.541 |
| EBV-LPD within 180 days, n (%) | 9 (10.6) | 2 (2.4) | 0.029 |
| CMV reactivation within 100 days, n (%) | 68 (80) | 65 (76) | 0.47 |
| Time to the first CMV reactivation, days | 34 (22–54) | 38 (21–96) | 0.003 |
| Acute GVHD, n (%) | |||
| Grade I–IV | 51 (60) | 47 (55) | 0.535 |
| Grade III–IV | 14 (16) | 7 (8) | 0.103 |
| Onset time of aGVHD, days | 26 (9–67) | 20 (12–84) | 0.548 |
| Actural 1-year survival, n (%) | 58 (68) | 73 (86) | 0.006 |
aGVHD, acute graft-versus-host disease; CMV, cytomegalovirus; EBV, Epstein-Barr virus.